BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
China CAR T
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Wednesday, May 1, 2024
See today's BioWorld
Home
» Biogen Gains Rights To UCB's CDP323 In $200M Partnership
X
Upgrade your daily dose of biopharma and medtech news
Subscribe to BioWorld™ news services
See subscription options
To read the full story,
subscribe
or
sign in
.
Biogen Gains Rights To UCB's CDP323 In $200M Partnership
Oct. 4, 2006
By
Jennifer Boggs
No Comments
Adding a fifth product to its portfolio of approved and investigational multiple sclerosis therapies, Biogen Idec Inc. agreed to collaborate on CDP323, an oral alpha-4 integrin inhibitor discovered by UCB. (BioWorld Today)
BioWorld